TMDI - Titan Medical Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5579
+0.0276 (+5.20%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.5303
Open0.5201
Bid0.5579 x 900
Ask0.5598 x 3000
Day's Range0.5101 - 0.5700
52 Week Range0.3800 - 4.6500
Volume312,182
Avg. Volume642,957
Market Cap18M
Beta (3Y Monthly)6.15
PE Ratio (TTM)N/A
EPS (TTM)-1.9500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • Business Wire

    Titan Medical Confirms Receipt of Deficiency Notices From Nasdaq

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery ("MIS"), today announced that on November 27, 2019, the Company received notification from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares (the "Shares") listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the Shares to maintain a minimum bid price of US$1.00 per Share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the Shares is below US$1.00 for a period of 30 consecutive business days.

  • Business Wire

    Titan Medical to Participate in Two Investment Conferences in December

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that Company management will be participating in two upcoming investor conferences. The Benchmark Company’s 8th Annual Discovery One on One Investor Conference being held at the New York Athletic Club in New York City on Wednesday, December 4, 2019. The 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the Lotte New York Palace in New York City.

  • Business Wire

    Titan Medical Reports Third Quarter 2019 Financial Results

    Titan Medical Inc. , a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery , announces financial results for the three and nine months ended September 30, 2019.

  • Business Wire

    Titan Medical Determines Not to Proceed with Public Offering

    Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has determined not to proceed with the public offering of units of the Company for which it filed a final short form prospectus on October 31, 2019. The Company has made this decision based on its assessment of market conditions, and intends to pursue alternative financing options. Titan Medical Inc. is focused on computer-assisted robotic surgical technologies for application in MIS.

  • Business Wire

    Titan Medical Announces Filing of Final Prospectus

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has filed and been receipted for a final short form prospectus (the “Final Prospectus”) in connection with the previously announced marketed offering (the “Offering”) of units of the Company (the “Units”) at a price of US $0.45 per Unit for minimum gross proceeds of US $15,000,000 and maximum gross proceeds of US $25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).

  • Business Wire

    Titan Medical Announces Pricing of Marketed Offering

    Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $0.45 per Unit for total gross proceeds of a minimum of US $15,000,000 and a maximum of US $25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).

  • Benzinga

    The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...

  • Business Wire

    Titan Medical Announces Filing of Amended and Restated Preliminary Prospectus and Withdrawal of Previously Published Milestones

    Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has filed and been receipted for an amended and restated preliminary short form prospectus (the “A&R Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan has also filed a corresponding registration statement on Form F-10 (the “Registration Statement”) with the United States Securities and Exchange Commission under the U.S.-Canada Multijurisdictional Disclosure System. Each of these filings is in connection with a proposed marketed offering of units (the “Units”) of the Company (the “Offering”) for total gross proceeds of a minimum of US$15,000,000 and a maximum of US$25,000,000.

  • Business Wire

    Titan Medical Continues to Market Offering of Units

    Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced on Monday, September 23, 2019 that it had filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan had also filed a corresponding registration statement on Form F-10 (the “Registration Statement”) with the United States Securities and Exchange Commission under the U.S.-Canada Multijurisdictional Disclosure System. On September 24, 2019, the Company announced that in consultation with its financial advisors it had switched from an overnight marketed offering to a fully marketed offering (the “Offering”) and that it expected to price the offering no later than September 27, 2019.

  • The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...

  • Zacks Small Cap Research

    TMDI: Titan Medical: Revolutionizing Minimally Invasive Surgery with Robotics!

    Titan Medical Inc. (TMD.TO) (TMDI) based in Toronto, Canada designs and develops computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). In the last decade, Titan has been focused on developing a single-port system for abdominal surgery which promises ease of use, design characteristics for superior clinical performance, operating room efficiency and cost benefit to hospitals. Stability and consistency of outcomes are of prime importance in interventional procedures since anatomical structures are complex and can be punctured easily.

  • Business Wire

    Titan Medical to Present and Exhibit at the Society of Robotic Surgery 2019 Annual Meeting

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that David McNally, President and CEO of Titan Medical, will present in the plenary session titled “Innovations in Robotic Technologies, What The Future Holds In Store” on Thursday, June 20 at the Society of Robotic Surgery 2019 Annual Meeting in Orlando. This industry-focused plenary session will feature executives from companies recognized for current and promising technology platforms in robotic surgery.

  • Titan Medical (TMDI) Shows Promise on Strategic Developments
    Zacks

    Titan Medical (TMDI) Shows Promise on Strategic Developments

    Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.